|
C16ORF87 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.38090000545432E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.09690000030349E-07 |
| Normal-vs-Stage2 |
2.09399999999693E-05 |
| Normal-vs-Stage3 |
2.38980000011324E-07 |
| Normal-vs-Stage4 |
1.023200000283E-07 |
| Stage1-vs-Stage2 |
6.524400E-01 |
| Stage1-vs-Stage3 |
2.465600E-01 |
| Stage1-vs-Stage4 |
9.770400E-02 |
| Stage2-vs-Stage3 |
7.180800E-01 |
| Stage2-vs-Stage4 |
3.667400E-01 |
| Stage3-vs-Stage4 |
5.209000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.16939999695154E-08 |
| Normal-vs-AfricanAmerican |
6.223200E-04 |
| Normal-vs-Asian |
7.72020000039397E-07 |
| Caucasian-vs-AfricanAmerican |
8.297000E-01 |
| Caucasian-vs-Asian |
6.175600E-01 |
| AfricanAmerican-vs-Asian |
5.818000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.18920000002909E-06 |
| Normal-vs-Female |
1.44759999542998E-08 |
| Male-vs-Female |
4.810600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.19640000004495E-06 |
| Normal-vs-Age(41-60Yrs) |
5.19090004313938E-09 |
| Normal-vs-Age(61-80Yrs) |
1.19080000005045E-06 |
| Normal-vs-Age(81-100Yrs) |
3.158500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.317600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.670600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.854000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.169800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.129600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.708400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.453800E-01 |
| Classical-VS-Follicular |
4.938600E-01 |
| Classical-VS-Other |
9.497200E-01 |
| Classical-VS-Normal |
3.40749999994117E-07 |
| Tall-VS-Follicular |
5.239400E-01 |
| Tall-VS-Other |
5.693400E-01 |
| Tall-VS-Normal |
2.15489999999541E-06 |
| Follicular-VS-Other |
8.748400E-01 |
| Follicular-VS-Normal |
1.78829999997188E-06 |
| Other-VS-Normal |
2.488400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.74330000330048E-08 |
| Normal-vs-N1 |
2.00380000037192E-07 |
| N0-vs-N1 |
4.409800E-01 |
|
|
